Drug Trial Radar · NCT05827081
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,466
Actual
Start
Feb 28, 2024
Primary completion
Sep 7, 2029
Study completion Sep 20, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).
Conditions
- Early Breast Cancer
Interventions
RibociclibDrug
Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest
LetrozoleDrug
Letrozole 2.5 mg orally once daily continuously
AnsastrozoleDrug
Anastrozole 1 mg orally once daily continuously.
GoserelinDrug
Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used
LeuprolideDrug
Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used
ExemestaneDrug
Exemestane 25 mg once daily continuously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Breast Cancer Free Survival (iBCFS) rate at 3 yearsTime frame: At 3 years
Locations
214 sites in 16 countries. Site status is shown where the registry gives one.
Central Alabama Research
Birmingham, Alabama
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Western Reg MC-COH Phoenix
Goodyear, Arizona
CARTI Cancer Center
Little Rock, Arkansas
Beverly Hills Cancer Center
Beverly Hills, California
Onco Inst of Hope and Innovation
Cerritos, California
City of Hope National Medical
Duarte, California
Providence Medical Foundation
Fullerton, California
Los Angeles Cancer Network Good Samaritan
Los Angeles, California
El Camino Hospital
Mountain View, California
Palo Alto Medical Foundation
Mountain View, California
UC Irvine Medical Center
Orange, California
Sutter Inst Medical Research
Sacramento, California
School Of Medicine
Sacramento, California
Sharp Rees Stealy Medical Group Inc
San Diego, California
Rocky Mountain Cancer Centers
Denver, Colorado
Georgetown University Lombardi Cancer Center
Washington D.C., District of Columbia
Medstar Washington Hospital Center
Washington D.C., District of Columbia
AdventHealth Altamonte Springs
Altamonte Springs, Florida
Holy Cross Health
Fort Lauderdale, Florida
Hialeah Hospital
Hialeah, Florida
Memorial Cancer Institute
Hollywood, Florida
Jupiter Medical Center
Jupiter, Florida
Ocala Research Institute Inc
Ocala, Florida
Summit Cancer Care PC
Savannah, Georgia
Affiliated Oncologists IL
Chicago, Illinois
Hope And Healing Care
Hinsdale, Illinois
Midwestern Reg MC COH Chicago
Zion, Illinois
Investigative Clinical R of Indiana
Indianapolis, Indiana
University of Iowa Health Care
Waukee, Iowa
University of Kansas Cancer Center
Westwood, Kansas
Cancer Center of Kansas
Wichita, Kansas
Willis-Knighton Cancer Center
Shreveport, Louisiana
Mercy Medical Center
Baltimore, Maryland
Maryland Oncology Hematology P A
Silver Spring, Maryland
Boston Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Minnesota Oncology Hematology P A
Minneapolis, Minnesota
Allina Hlth Cancer Inst Minneapolis
Minneapolis, Minnesota
Jackson Oncology Associates
Jackson, Mississippi
Showing 40 of 214 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.